• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ATAI Life Sciences N.V.

    3/1/22 4:30:22 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATAI alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    ATAI Life Sciences N.V.

    (Name of Issuer)

     

    Common Shares

    (Title of Class of Securities)

     

    N0731H103

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. N0731H103

     

    (1)

    Names of reporting persons:

     

    Galaxy Group Funding (ECI) (U) LLC

    (2)

    Check the appropriate box if a member of a group (see instructions)

    (a) ☐

    (b) ☐

    (3)

    SEC use only

     

     

    (4)

    Citizenship or place of organization:

     

    Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person with

    (5)

    Sole voting power:

     

    0

    (6)

    Shared voting power:

     

    10,796,736

    (7)

    Sole dispositive power:

     

    0 

    (8)

    Shared dispositive power:

     

    10,796,736

    (9)

    Aggregate amount beneficially owned by each reporting person:

     

    10,796,736

    (10)

    Check if the aggregate amount in row (9) excludes certain shares (see instructions):

     

    ☐

    (11)

    Percent of class represented by amount in row (9):

     

    6.7%

    (12)

    Type of reporting person (see instructions):

     

    OO

     

     

     

     

    CUSIP No. N0731H103

     

    (1)

    Names of reporting persons:

     

    Galaxy Group Investments LLC

    (2)

    Check the appropriate box if a member of a group (see instructions)

    (a) ☐

    (b) ☐

    (3)

    SEC use only

     

     

    (4)

    Citizenship or place of organization:

     

    Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person with

    (5)

    Sole voting power:

     

    0

    (6)

    Shared voting power:

     

    10,796,736

    (7)

    Sole dispositive power:

     

    0

    (8)

    Shared dispositive power:

     

    10,796,736

    (9)

    Aggregate amount beneficially owned by each reporting person:

     

    10,796,736

    (10)

    Check if the aggregate amount in row (9) excludes certain shares (see instructions):

     

    ☐

    (11)

    Percent of class represented by amount in row (9):

     

    6.7%

    (12)

    Type of reporting person (see instructions):

     

    OO

     

     

     

     

    CUSIP No. N0731H103

     

    (1)

    Names of reporting persons:

     

    Michael E. Novogratz

    (2)

    Check the appropriate box if a member of a group (see instructions)

    (a) ☐

    (b) ☐

    (3)

    SEC use only

     

     

    (4)

    Citizenship or place of organization:

     

    Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person with

    (5)

    Sole voting power:

     

    0

    (6)

    Shared voting power:

     

    10,796,736

    (7)

    Sole dispositive power:

     

    0 

    (8)

    Shared dispositive power:

     

    10,796,736

    (9)

    Aggregate amount beneficially owned by each reporting person:

     

    10,796,736

    (10)

    Check if the aggregate amount in row (9) excludes certain shares (see instructions):

     

    ☐

    (11)

    Percent of class represented by amount in row (9):

     

    6.7%

    (12)

    Type of reporting person (see instructions):

     

    IN

     

     

     

     

    Item 1(a). Name of issuer:

     

    ATAI Life Sciences N.V. (the “Issuer”)

     

    Item 1(b). Address of issuer’s principal executive offices:

     

    ATAI Life Sciences N.V. c/o Mindspace

    Krausenstraße 9-10

    Berlin, Germany

     

    Item 2(a). Name of person filing:

     

    This Schedule 13G is being filed by: (i) Galaxy Group Funding (ECI) (U) LLC, a Delaware limited liability company (“GGF”), (ii) Galaxy Group Investments LLC, a Delaware limited liability company (“GGI”), and (iii) Michael E. Novogratz (all of the foregoing, collectively, the “Reporting Persons”). GGF is the holder of record of the Common Shares reported in this Schedule 13G. GGI is the manager of GGF and Michael E. Novogratz is the manager of GGI. GGI and Michael E. Novogratz may be deemed to share beneficial ownership of the Common Shares held of record by GGF.

     

    Item 2(b). Address of principal business office or, if none, residence:

     

    The principal business office of the Reporting Persons is:

     

    107 Grand Street, 7th Floor

    New York, NY 10013

     

    Item 2(c). Citizenship:

     

    GGF and GGI are limited liability companies organized in Delaware.

     

    Michael E. Novogratz is a United States citizen.

     

    Item 2(d). Title of Class of Securities:

     

    Common Shares, par value €0.10 per share (“Common Shares”)

     

    Item 2(e). CUSIP No.:

     

    N0731H103

     

    Item 3.

     

    Not Applicable.

     

    Item 4. Ownership

     

    The ownership information below represents beneficial ownership by the Reporting Persons of the Common Shares of the Issuer as of December 31, 2021, based upon 160,297,952 Common Shares outstanding as of November 1, 2021, as reported by the Issuer in its Quarterly Report on Form 10-Q for the period ended September 30, 2021 filed with the Securities and Exchange Commission on November 15, 2021.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not Applicable.

     

     

     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

     

    Item 10. Certification

     

    Not Applicable.

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Document
         
    99.1   Joint Filing Agreement, dated February 22, 2022, among the Reporting Persons

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Galaxy Group Funding (ECI) (U) LLC
         
    February 22, 2022 By: /s/ Vincent Barbuto
      Name: Vincent Barbuto
      Title: Chief Financial Officer
         
      Galaxy Group Investments LLC
         
    February 22, 2022 By: /s/ Vincent Barbuto
      Name: Vincent Barbuto
      Title: Chief Financial Officer
         
    February 22, 2022 By: /s/ Michael E. Novogratz
      Name: Michael E. Novogratz

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

     

     

     

    Get the next $ATAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATAI

    DatePrice TargetRatingAnalyst
    1/20/2026$11.00Buy
    Guggenheim
    10/13/2025$12.00Buy
    Needham
    7/29/2025$14.00Outperform
    Oppenheimer
    4/4/2025Buy
    Berenberg
    11/18/2024$15.00 → $10.00Buy
    H.C. Wainwright
    4/3/2024$6.00Hold → Buy
    Maxim Group
    11/1/2022$18.00Buy
    Loop Capital
    11/30/2021$25.00Buy
    Maxim Group
    More analyst ratings

    $ATAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Feilding-Mellen Cosmo

    4 - Atai Beckley N.V. (0001840904) (Issuer)

    11/26/25 5:00:26 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hershberg Robert

    4 - Atai Beckley N.V. (0001840904) (Issuer)

    11/6/25 8:54:40 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Feilding-Mellen Cosmo was granted 7,702,990 shares (SEC Form 4)

    4 - Atai Beckley N.V. (0001840904) (Issuer)

    11/6/25 8:49:06 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    SEC Filings

    View All

    SEC Form 15-12G filed by Atai Beckley N.V

    15-12G - Atai Beckley N.V. (0001840904) (Filer)

    12/30/25 9:01:02 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POSASR filed by Atai Beckley N.V

    POSASR - Atai Beckley N.V. (0001840904) (Filer)

    12/30/25 8:49:58 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atai Beckley N.V filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Atai Beckley N.V. (0001840904) (Filer)

    12/5/25 4:56:59 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation

    NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the peer-reviewed publication of results from its ongoing four-part Phase 2a study (NCT05660642) evaluating BPL-003 (mebufotenin benzoate nasal spray) in patients with treatment-resistant depression (TRD). Published in the Journal of Psychopharmacology, the newly reported data come from Cohort 1 – a 12 week, open-label trial of a single 10 mg intranasal dose of BPL-003 in 12 patients with moderate-to-severe TRD wh

    3/17/26 6:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

    BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway reaffirmed through the planned early-2029 topline readouts from both parallel Phase 3 pivotal studiesCommercial readiness advancing with scalable treatment model aligned to existing interventional psychiatry workflowsContinued pipeline progress, including positive Phase 2a results for EMP‑01 and expected Phase 2 topline for VLS-01 in H2 2026Replay and presentation materials available on AtaiBeckley's investor website NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology c

    3/10/26 6:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions

    Issued on behalf of Cybin D/B/A Helus PharmaUSANewsGroup.com News CommentaryVANCOUVER, BC, March 9, 2026 /CNW/ -- The central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials and regulatory milestones accumulate1. The Drug Enforcement Administration raised its 2026 production quotas for controlled research compounds by 67%, reflecting expanding clinical trial activity across the therapeutics landscape2. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), a

    3/9/26 10:50:00 AM ET
    $ATAI
    $CMPS
    $DFTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $ATAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on AtaiBeckley with a new price target

    Guggenheim initiated coverage of AtaiBeckley with a rating of Buy and set a new price target of $11.00

    1/20/26 9:22:21 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on atai Life Sciences N.V. with a new price target

    Needham initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $12.00

    10/13/25 8:51:27 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on atai Life Sciences N.V. with a new price target

    Oppenheimer initiated coverage of atai Life Sciences N.V. with a rating of Outperform and set a new price target of $14.00

    7/29/25 7:39:06 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Apeiron Investment Group Ltd. bought $19,000,000 worth of shares (8,675,799 units at $2.19) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    8/18/25 6:00:05 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Apeiron Investment Group Ltd. bought $2,520,000 worth of shares (1,800,000 units at $1.40) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    3/24/25 5:00:18 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Apeiron Investment Group Ltd. bought $22,755,008 worth of shares (10,835,718 units at $2.10) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    2/19/25 6:00:05 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Financials

    Live finance-specific insights

    View All

    AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

    EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profileEMP-01 demonstrated a clinically meaningful placebo-adjusted least squares mean reduction of 11.85 points on the Liebowitz Social Anxiety Scale (LSAS) at Day 43 (Hedges' g = 0.45; p-value = 0.036, one-tailed)EMP-01 demonstrated a robust separation from placebo on the Clinician Global Impression–Improvement (CGI-I) assessment: 49% responders vs. 15% for placebo, corresponding to a Number Needed to Treat (NNT) of 2.95EMP-01 demonstrated improvements across both Fear and Avoidance sub-domains of the LSAS, including improvement in social avoidance behavio

    2/26/26 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression

    A 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg dose in the core study of the Phase 2b clinical trial produced additional rapid, clinically meaningful antidepressant effects that were sustained for up to eight weeksPatients who received an active dose of BPL-003 in the core study of the Phase 2b clinical trial (either 8 mg or 12 mg) met response and remission criteria for depression at increased rates after receiving a 12 mg dose in the OLE study, with 63% in response and 48% in remission at Week 8 in the OLE study (Week 16 of the Phase 2b clinical trial)An End-of-Phase 2 meeting has been scheduled with the U.S. Food

    11/10/25 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

    Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single doseBoth 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8BPL-003 was generally well-tolerated at all doses, with 99% of treatment-emergent adverse events being mild or moderate, and no drug-related serious adverse events or suicide-related safety signalsMajority of patients deemed ready for discharge at the 90 minutes post-dose assessment, which suggests BPL-003 could fit within t

    7/1/25 6:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Leadership Updates

    Live Leadership Updates

    View All

    AtaiBeckley Appoints Michael Faerm as Chief Financial Officer

    NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026. Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investment banking. As Chief Financial Officer at AtaiBeckley, he will lead the Company's financial strategy, capital markets activities, and overall financial operations. Anne Johnson, who ha

    2/19/26 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

    - Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao M.D., Ph.D., has assumed the role of sole Chief Executive Officer (CEO), joined by the promotions of Kevin Craig, M.D.

    1/10/25 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

    NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory board ("Board") subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer ("CEO") and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operati

    5/23/24 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ATAI Life Sciences N.V.

    SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

    9/27/24 7:56:26 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)

    SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

    5/3/24 4:06:02 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)

    SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

    3/12/24 9:30:31 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care